Christine B Boers-Doets - Academia.edu (original) (raw)
Uploads
Papers by Christine B Boers-Doets
Seminars in Oncology Nursing, Dec 31, 2023
TVZ - Verpleegkunde in praktijk en wetenschap, Nov 30, 2023
The Lancet Oncology, 2001
Ortner share some information regarding the Supportive Care Group in the German Cancer Society. D... more Ortner share some information regarding the Supportive Care Group in the German Cancer Society. Dr. Ortner studied pharmaceutical sciences in Braunschweig, and completed her PhD thesis in pharmaceutical chemistry in Dusseldorf. She's held several positions in clinical research and marketing in pharmaceutical companies with an emphasis on oncologic medications. Since 1996 Dr. Ortner has had more than 100 publications and press articles in several German journals, and in the media. The medical communication company POMME-med (Petra Ortner Medical Management Enterprises) was founded by Dr. Ortner in 1996, and she has been a press representative and board member of the German Supportive working group association (Arbeitskreis Supportive MaBnahmen in der Onkologie, ASO) as well as a current board member of the working group of oncological pharmacists (OPH) in the German Cancer Society.
Journal of The National Cancer Institute Monographs, Aug 1, 2019
Supportive Care in Cancer, Aug 14, 2013
Radiation dermatitis (RD) results from radiotherapy and often occurs within the first 4 weeks of ... more Radiation dermatitis (RD) results from radiotherapy and often occurs within the first 4 weeks of treatment, although late effects also occur. While RD may resolve over time, it can have a profound effect on patients' quality of life and lead to dose modifications. A study group of international, interdisciplinary experts convened to develop RD prevention and treatment guidelines based on evidence from randomized, controlled trials. Evidence-based recommendations were developed after an extensive literature review. Randomized, controlled trials with standardized measurement of outcomes were considered the best evidence, and a majority of the recommendations were formulated from this literature. The adoption of washing with water, with or without a mild soap, and allowing the use of antiperspirants is supported by randomized trials. Use of topical prophylactic corticosteroids (mometasone) is recommended to reduce discomfort and itching. There is some evidence that silver sulfadiazine cream can reduce dermatitis score. There is insufficient evidence to support, and therefore the panel recommends against the use of trolamine, topical sulcrate, hyaluronic acid, ascorbic acid, silver leaf dressing, light-emitting diode lasers, Theta cream, dexpanthenol, calendula, proteolytic enzymes, sulcralfate, oral zinc, and pentoxifylline. Moreover, there is no evidence to support the superiority for any specific intervention in a reactive fashion. For patients with established radiation-induced telangiectasia and fibrosis, the panel suggests the use of pulse dye laser for visual appearance, and the use of pentoxifylline and vitamin E for the reduction of fibrosis.
Annals of Oncology, 2018
Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast ca... more Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3yearsanda5−yearsurvivalofonly3 years and a 5-year survival of only 3yearsanda5−yearsurvivalofonly25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8]. The last decade has seen an improvement in the levels of evidence (LoEs) used for many of the ABC recommendations, however, still far from the LoEs existing for the majority of early
Key Words. Tyrosine kinase inhibitor • Mammalian target of rapamycin inhibitor • Oral adverse eve... more Key Words. Tyrosine kinase inhibitor • Mammalian target of rapamycin inhibitor • Oral adverse events • Mucositis •
Key Words. Tyrosine kinase inhibitor • Mammalian target of rapamycin inhibitor • Oral adverse eve... more Key Words. Tyrosine kinase inhibitor • Mammalian target of rapamycin inhibitor • Oral adverse events • Mucositis • Aphthous stomatitis • Renal cell carcinoma
Background Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side ... more Background Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recom-mendations for EGFRI-associated dermatologic toxicities. Methods A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recom-mendations for EGFRI-associated dermatologic toxicities. Results Prophylactic and reactive recommendations for pap-ulopustular (acneiform) rash, hair changes, radiation derma-titis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. Conclusion Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intens...
Background: EGFR inhibitors produce various dermatologic side effects in the majority of patients... more Background: EGFR inhibitors produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI associated dermatologic toxicities. Methods: A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI associated dermatologic toxicities. Results: Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/ fissures and paronychia are presented, as well as general dermatologic recommendations when possible. Conclusion: Prevention and management of EGFRI related dermatologic toxicities is critical to maintain patients’ health related quality of life and dose intensity of antineoplastic regimens. More...
This thesis presents three notable findings: the voice of the patient is inconsequently incorpora... more This thesis presents three notable findings: the voice of the patient is inconsequently incorporated in scientific research regarding adverse events; available instruments may be of limited value for approaching targeted therapy-associated mucocutaneous adverse events; and available knowledge about a patient-driven approach to adverse events is not broadly incorporated in research and clinical care. The voice of the patient is inconsequently incorporated in scientific research and the healthcare-professional plays the central role in adverse event diagnosis and management. The incidence of the adverse events is mainly measured by healthcare-professionals with suboptimal scales. As a result there may be underreporting of adverse events. In addition, the non-validated CTCAE scoring system for the grading of the adverse events is most commonly used while more precise grading instruments are available. Currently, most adverse events grading is performed by healthcare-professionals rathe...
Supportive Care in Cancer, 2014
PurposeDermatologic adverse events (dAEs) in cancer treatment are frequent with the use of target... more PurposeDermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.MethodsA comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of developmen...
Supportive Care in Cancer, 2020
Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking... more Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking and multiple care and management strategies are used. The main purpose of the present study is to gain information about the different skincare products being used against skin reactions in metastatic colorectal cancer (mCRC) and recurrent/metastatic (R/M) or locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) patients treated with cetuximab. An open-label, prospective observational study conducted in the Netherlands. The occurrence of skin reactions and the care and management options taken were documented for 16 weeks, starting from the first administration of cetuximab. A total of 103 patients were included in 7 hospitals. 38 patients (37%) developed a grade ≥ 2 skin reaction. Eighty-six patients could be analysed for the primary endpoint (73.3% males, mean age 62.4 years, n = 44 LA SCCHN, n = 16 R/M SCCHN, n = 26 mCRC). The most frequently used skin products at s...
European Journal of Cancer, 2015
European Journal of Oncology Nursing, 2014
European Journal of Oncology Nursing, 2014
Seminars in Oncology Nursing, Dec 31, 2023
TVZ - Verpleegkunde in praktijk en wetenschap, Nov 30, 2023
The Lancet Oncology, 2001
Ortner share some information regarding the Supportive Care Group in the German Cancer Society. D... more Ortner share some information regarding the Supportive Care Group in the German Cancer Society. Dr. Ortner studied pharmaceutical sciences in Braunschweig, and completed her PhD thesis in pharmaceutical chemistry in Dusseldorf. She's held several positions in clinical research and marketing in pharmaceutical companies with an emphasis on oncologic medications. Since 1996 Dr. Ortner has had more than 100 publications and press articles in several German journals, and in the media. The medical communication company POMME-med (Petra Ortner Medical Management Enterprises) was founded by Dr. Ortner in 1996, and she has been a press representative and board member of the German Supportive working group association (Arbeitskreis Supportive MaBnahmen in der Onkologie, ASO) as well as a current board member of the working group of oncological pharmacists (OPH) in the German Cancer Society.
Journal of The National Cancer Institute Monographs, Aug 1, 2019
Supportive Care in Cancer, Aug 14, 2013
Radiation dermatitis (RD) results from radiotherapy and often occurs within the first 4 weeks of ... more Radiation dermatitis (RD) results from radiotherapy and often occurs within the first 4 weeks of treatment, although late effects also occur. While RD may resolve over time, it can have a profound effect on patients' quality of life and lead to dose modifications. A study group of international, interdisciplinary experts convened to develop RD prevention and treatment guidelines based on evidence from randomized, controlled trials. Evidence-based recommendations were developed after an extensive literature review. Randomized, controlled trials with standardized measurement of outcomes were considered the best evidence, and a majority of the recommendations were formulated from this literature. The adoption of washing with water, with or without a mild soap, and allowing the use of antiperspirants is supported by randomized trials. Use of topical prophylactic corticosteroids (mometasone) is recommended to reduce discomfort and itching. There is some evidence that silver sulfadiazine cream can reduce dermatitis score. There is insufficient evidence to support, and therefore the panel recommends against the use of trolamine, topical sulcrate, hyaluronic acid, ascorbic acid, silver leaf dressing, light-emitting diode lasers, Theta cream, dexpanthenol, calendula, proteolytic enzymes, sulcralfate, oral zinc, and pentoxifylline. Moreover, there is no evidence to support the superiority for any specific intervention in a reactive fashion. For patients with established radiation-induced telangiectasia and fibrosis, the panel suggests the use of pulse dye laser for visual appearance, and the use of pentoxifylline and vitamin E for the reduction of fibrosis.
Annals of Oncology, 2018
Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast ca... more Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3yearsanda5−yearsurvivalofonly3 years and a 5-year survival of only 3yearsanda5−yearsurvivalofonly25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8]. The last decade has seen an improvement in the levels of evidence (LoEs) used for many of the ABC recommendations, however, still far from the LoEs existing for the majority of early
Key Words. Tyrosine kinase inhibitor • Mammalian target of rapamycin inhibitor • Oral adverse eve... more Key Words. Tyrosine kinase inhibitor • Mammalian target of rapamycin inhibitor • Oral adverse events • Mucositis •
Key Words. Tyrosine kinase inhibitor • Mammalian target of rapamycin inhibitor • Oral adverse eve... more Key Words. Tyrosine kinase inhibitor • Mammalian target of rapamycin inhibitor • Oral adverse events • Mucositis • Aphthous stomatitis • Renal cell carcinoma
Background Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side ... more Background Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recom-mendations for EGFRI-associated dermatologic toxicities. Methods A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recom-mendations for EGFRI-associated dermatologic toxicities. Results Prophylactic and reactive recommendations for pap-ulopustular (acneiform) rash, hair changes, radiation derma-titis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. Conclusion Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients’ health-related quality of life and dose intens...
Background: EGFR inhibitors produce various dermatologic side effects in the majority of patients... more Background: EGFR inhibitors produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI associated dermatologic toxicities. Methods: A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI associated dermatologic toxicities. Results: Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/ fissures and paronychia are presented, as well as general dermatologic recommendations when possible. Conclusion: Prevention and management of EGFRI related dermatologic toxicities is critical to maintain patients’ health related quality of life and dose intensity of antineoplastic regimens. More...
This thesis presents three notable findings: the voice of the patient is inconsequently incorpora... more This thesis presents three notable findings: the voice of the patient is inconsequently incorporated in scientific research regarding adverse events; available instruments may be of limited value for approaching targeted therapy-associated mucocutaneous adverse events; and available knowledge about a patient-driven approach to adverse events is not broadly incorporated in research and clinical care. The voice of the patient is inconsequently incorporated in scientific research and the healthcare-professional plays the central role in adverse event diagnosis and management. The incidence of the adverse events is mainly measured by healthcare-professionals with suboptimal scales. As a result there may be underreporting of adverse events. In addition, the non-validated CTCAE scoring system for the grading of the adverse events is most commonly used while more precise grading instruments are available. Currently, most adverse events grading is performed by healthcare-professionals rathe...
Supportive Care in Cancer, 2014
PurposeDermatologic adverse events (dAEs) in cancer treatment are frequent with the use of target... more PurposeDermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.MethodsA comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of developmen...
Supportive Care in Cancer, 2020
Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking... more Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking and multiple care and management strategies are used. The main purpose of the present study is to gain information about the different skincare products being used against skin reactions in metastatic colorectal cancer (mCRC) and recurrent/metastatic (R/M) or locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) patients treated with cetuximab. An open-label, prospective observational study conducted in the Netherlands. The occurrence of skin reactions and the care and management options taken were documented for 16 weeks, starting from the first administration of cetuximab. A total of 103 patients were included in 7 hospitals. 38 patients (37%) developed a grade ≥ 2 skin reaction. Eighty-six patients could be analysed for the primary endpoint (73.3% males, mean age 62.4 years, n = 44 LA SCCHN, n = 16 R/M SCCHN, n = 26 mCRC). The most frequently used skin products at s...
European Journal of Cancer, 2015
European Journal of Oncology Nursing, 2014
European Journal of Oncology Nursing, 2014